The DOK2 (Docking Protein 2) antibody is a research tool targeting the DOK2 protein, a member of the DOK family of adaptor proteins involved in intracellular signaling. DOK2. encoded by the *DOK2* gene, acts as a downstream regulator of receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (e.g., ABL, SRC). It contains conserved domains, including a pleckstrin homology (PH) domain and phosphotyrosine-binding (PTB) domain, enabling interactions with signaling molecules. DOK2 plays roles in immune regulation, cell proliferation, and apoptosis, often functioning as a tumor suppressor by inhibiting oncogenic pathways like Ras-MAPK and PI3K-AKT. Its dysregulation is linked to cancers such as lung adenocarcinoma, leukemia, and gastrointestinal tumors. Antibodies against DOK2 are used in Western blotting, immunohistochemistry, and immunofluorescence to study its expression, localization, and post-translational modifications. Research highlights DOK2's dual role—either suppressing tumors via tyrosine phosphatase recruitment or promoting malignancy in specific contexts—underscoring its context-dependent behavior. These antibodies are critical for exploring DOK2's mechanistic contributions to diseases and its potential as a therapeutic target or biomarker.